INNOVENTIV IP

Who we are

Robert T. Hrubiec, Ph.D, J.D., President of Innoventiv IP, is a seasoned intellectual property attorney and business executive with over 30 years in-house experience as a scientist and in-house IP counsel in both large and small pharmaceutical and biotechnology companies.

Bob served as Vice President and Chief IP Counsel of Cephalon, Inc., a mid-sized biopharmaceutical company and as an Intellectual Property Attorney for GlaxoSmithKline, a multi-billion dollar pharmaceutical company.

Bob earned his doctoral degree in Synthetic Organic Chemistry from the University of Connecticut.  He also served a post-doctoral fellowship (Pharmacology/Biochemistry) at Yale University School of Medicine and earned his law degree from North Carolina Central University School of Law (evening division).  Bob has been a member of the North Carolina Bar since 1998, the Pennsylvania Bar since 2010 and a member of the United States Patent and Trademark Office Bar as a Patent Agent since 1992 and as a Patent Attorney since 2000.  Prior to his admission to the Patent Bar, Bob had various roles as a scientist in academics and the pharmaceutical industry.

Bob's passion for science, technology and the law along with his entrepreneurial spirit create smart, strategic solutions to the management of IP.

For more information visit Bob's LinkedIn page at LinkedIn.

Contact us for a complimentary consultation to discuss your IP needs.**

Pharmidable Legal Advisors

Through a separate consulting company, Pharmidable Legal Advisors, LLC, Bob and colleague Randy Zakreski, Esq. provide further creative, cutting-edge pharma/bio/device/diagnostic related life-cycle-management services to significantly increase IP and regulatory exclusivity value.

For more Information about Pharmidable's services, please visit www.pharmidablelegal.com

Selected accomplishments*

• Evaluated and advised on IP estates of several target companies/products which led to the acquisition of several companies and in-licensing of several development/commercial products (small molecules, formulations, monoclonal antibodies and stem cells) and billions in revenue

• Identified issues with target products/companies patent estates which significantly reduced the overall deal value and resulted in hundreds of millions in savings

• Managed outside counsel resulting in significant cost savings

• Identified and implemented strategies that significantly reduced patent costs and resulted in savings of hundreds of thousands for a single patent family

• Received Deals of Distinction award from the Licensing Executives Society which recognized a creative IP-based licensing and business arrangement in the stem cell business sector

• Identified and implemented IP and regulatory strategies that significantly increased IP protection for key products and extended product protection by several years

• Identified and obtained additional patents to prevent design around products and significantly increased patent protection for major products (identified several new patents around a single key product)

• Assisted in managing patent litigation for a major product which resulted in several years of exclusivity and billions in revenue

• Identified and obtained creative patent protection for a key product which extended exclusivity for fifteen years

• Devised a combined patent/FDA creative strategy for a key product which extended protection for several years

• Leveraged the patent estate of a product which resulted in a significant negotiated reduction in payments to a collaborator

Please note that prior results do not predict, warrant or guarantee a similar outcome, since results will vary depending on the facts and circumstances of each individual matter.